Therapeutic vaccines

References

• Stein WD, Gulley JL, Schlom J, Madan RA, Dahut W, Figg WD, et al. Tumor regression and growth rates determined in five intramural NCI prostate cancer trials: the growth rate constant as an indicator of therapeutic efficacy. Clin Cancer Res 2011; 17:907 - 17; http://dx.doi.org/10.1158/1078-0432.CCR-10-1762; PMID: 21106727
   PubMed Web of Science ®Google Scholar
• Madan RA, Gulley JL, Fojo T, Dahut WL. Therapeutic cancer vaccines in prostate cancer: the paradox of improved survival without changes in time to progression. Oncologist 2010; 15:969 - 75; http://dx.doi.org/10.1634/theoncologist.2010-0129; PMID: 20798195
   PubMed Web of Science ®Google Scholar
• Schlom J, Arlen PM, Gulley JL. Cancer vaccines: moving beyond current paradigms. Clin Cancer Res 2007; 13:3776 - 82; http://dx.doi.org/10.1158/1078-0432.CCR-07-0588; PMID: 17606707
   PubMed Web of Science ®Google Scholar
• Bilusic M, Gulley JL. Endpoints, patient selection, and biomarkers in the design of clinical trials for cancer vaccines. Cancer Immunol Immunother 2012; 61:109 - 17; http://dx.doi.org/10.1007/s00262-011-1141-0; PMID: 22120693
   PubMed Web of Science ®Google Scholar
• Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711 - 23; http://dx.doi.org/10.1056/NEJMoa1003466; PMID: 20525992
   PubMed Web of Science ®Google Scholar
• Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al, IMPACT Study Investigators. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363:411 - 22; http://dx.doi.org/10.1056/NEJMoa1001294; PMID: 20818862
   PubMed Web of Science ®Google Scholar
• Gajewski TF. Failure at the effector phase: immune barriers at the level of the melanoma tumor microenvironment. Clin Cancer Res 2007; 13:5256 - 61; http://dx.doi.org/10.1158/1078-0432.CCR-07-0892; PMID: 17875753
   PubMed Web of Science ®Google Scholar
• Hale DF, Clifton GT, Sears AK, Vreeland TJ, Shumway N, Peoples GE, et al. Cancer vaccines: should we be targeting patients with less aggressive disease?. Expert Rev Vaccines 2012; 11:721 - 31; http://dx.doi.org/10.1586/erv.12.39; PMID: 22873128
   PubMed Web of Science ®Google Scholar
• Gulley JL, Madan RA, Schlom J. Impact of tumour volume on the potential efficacy of therapeutic vaccines. Curr Oncol 2011; 18:e150 - 7; http://dx.doi.org/10.3747/co.v18i3.783; PMID: 21655153
   PubMed Web of Science ®Google Scholar
• Gulley JL, Drake CG. Immunotherapy for prostate cancer: recent advances, lessons learned, and areas for further research. Clin Cancer Res 2011; 17:3884 - 91; http://dx.doi.org/10.1158/1078-0432.CCR-10-2656; PMID: 21680544
   PubMed Web of Science ®Google Scholar
• Rotow J, Gameiro SR, Madan RA, Gulley JL, Schlom J, Hodge JW. Vaccines as monotherapy and in combination therapy for prostate cancer. Clin Transl Sci 2010; 3:116 - 22; http://dx.doi.org/10.1111/j.1752-8062.2010.00186.x; PMID: 20590682
   PubMed Web of Science ®Google Scholar
• Hodge JW, Guha C, Neefjes J, Gulley JL. Synergizing radiation therapy and immunotherapy for curing incurable cancers. Opportunities and challenges. Oncology 2008; 22:1064 - 70
   PubMed Web of Science ®Google Scholar
• Brandmaier AG, Leitner WW, Ha SP, Sidney J, Restifo NP, Touloukian CE. High-avidity autoreactive CD4+ T cells induce host CTL, overcome T(regs) and mediate tumor destruction. J Immunother 2009; 32:677 - 88; http://dx.doi.org/10.1097/CJI.0b013e3181ab1824; PMID: 19561540
   PubMed Web of Science ®Google Scholar
• Kudo-Saito C, Schlom J, Hodge JW. Induction of an antigen cascade by diversified subcutaneous/intratumoral vaccination is associated with antitumor responses. Clin Cancer Res 2005; 11:2416 - 26; http://dx.doi.org/10.1158/1078-0432.CCR-04-1380; PMID: 15788693
   PubMed Web of Science ®Google Scholar
• Hodge JW, Sharp HJ, Gameiro SR. Abscopal regression of antigen disparate tumors by antigen cascade after systemic tumor vaccination in combination with local tumor radiation. Cancer Biother Radiopharm 2012; 27:12 - 22; http://dx.doi.org/10.1089/cbr.2012.1202; PMID: 22283603
   PubMed Web of Science ®Google Scholar
• Gulley JL, Arlen PM, Bastian A, Morin S, Marte J, Beetham P, et al. Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer. Clin Cancer Res 2005; 11:3353 - 62; http://dx.doi.org/10.1158/1078-0432.CCR-04-2062; PMID: 15867235
   PubMed Web of Science ®Google Scholar
• Lechleider RJ, Arlen PM, Tsang KY, Steinberg SM, Yokokawa J, Cereda V, et al. Safety and immunologic response of a viral vaccine to prostate-specific antigen in combination with radiation therapy when metronomic-dose interleukin 2 is used as an adjuvant. Clin Cancer Res 2008; 14:5284 - 91; http://dx.doi.org/10.1158/1078-0432.CCR-07-5162; PMID: 18698048
   PubMed Web of Science ®Google Scholar
• Madan RA, Mohebtash M, Arlen PM, Vergati M, Rauckhorst M, Steinberg SM, et al. Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol 2012; 13:501 - 8; http://dx.doi.org/10.1016/S1470-2045(12)70006-2; PMID: 22326924
   PubMed Web of Science ®Google Scholar
• Disis ML, Wallace DR, Gooley TA, Dang Y, Slota M, Lu H, et al. Concurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancer. J Clin Oncol 2009; 27:4685 - 92; http://dx.doi.org/10.1200/JCO.2008.20.6789; PMID: 19720923
   PubMed Web of Science ®Google Scholar
• Hardwick N, Chain B. Epitope spreading contributes to effective immunotherapy in metastatic melanoma patients. Immunotherapy 2011; 3:731 - 3; http://dx.doi.org/10.2217/imt.11.62; PMID: 21668310
   PubMed Web of Science ®Google Scholar